STAAR Surgical (STAA) Aktievy
STAAR Surgical Company, tillsammans med sina dotterbolag, designar, utvecklar, tillverkar och säljer fakiska implanterbara linser för ögat och tillbehör för att föra in linserna i ögat. Mer information
| Snöflinga Score | |
|---|---|
| Värdering | 3/6 |
| Framtida tillväxt | 3/6 |
| Tidigare resultat | 2/6 |
| Finansiell hälsa | 6/6 |
| Utdelningar | 0/6 |
STAA Community Fair Values
Create NarrativeSee what 12 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
STAAR Surgical Company Konkurrenter
Prishistorik och prestanda
| Historiska aktiekurser | |
|---|---|
| Aktuell aktiekurs | US$20.82 |
| 52 veckors högsta | US$35.87 |
| 52 veckors lägsta | US$15.59 |
| Beta | 1.22 |
| 1 månads förändring | -15.57% |
| 3 månaders förändring | -28.50% |
| 1 års förändring | -23.57% |
| 3 års förändring | -47.17% |
| 5 års förändring | -85.39% |
| Förändring sedan börsintroduktionen | -12.34% |
Senaste nyheter och uppdateringar
Recent updates
Uppdatering av berättelse • Jul 29
STAA: Sector Procedure Risks And China Uncertainty Will Limit Future Upside
The analyst fair value estimate for STAAR Surgical has moved from $23.00 to $20.00, reflecting the new $20 UBS price target and more cautious assumptions, despite generally supportive comments on recent Q1 trends from other firms. Analyst Commentary Recent research on STAAR Surgical reflects a wide range of opinions, with some firms highlighting strong Q1 execution and others leaning more cautious on growth durability and valuation.Seeking Alpha • Jul 17
STAAR Surgical's Punishment For Opacity Is Just
Summary STAAR Surgical Company shares fell sharply after preliminary Q2 2026 sales met expectations but lacked forward guidance, raising investor concerns. STAA demonstrated robust revenue growth, especially in China and the Americas, with improved margins and cost discipline, but EMEA sales lagged due to geopolitical issues. Despite recent profitability and a strong cash position, uncertainty remains over the sustainability of these improvements and the absence of detailed guidance. I maintain a Sell rating on STAA stock, pending more substantive guidance at the August 12th earnings release to assess if recent gains are sustainable. Read the full article on Seeking AlphaUppdatering av berättelse • Jun 30
STAA: Limited China Visibility And Missing Guidance Will Constrain Future Rebound Confidence
The updated analyst price target for STAAR Surgical moves from an implied fair value of $16.00 to $23.00, reflecting adjustments to revenue growth, profit margin, and future P/E assumptions after stronger than expected Q1 results and increased confidence in a China rebound cited by several analysts. Analyst Commentary Recent Street research on STAAR Surgical has centered on stronger than expected Q1 results and growing attention on the China business, but not all commentary is uniformly bullish.Analysartikel • Jun 16
STAAR Surgical (STAA) Stock Could Be 4.4% Undervalued Despite Its Rich P S Multiple
Why STAAR Surgical Stock Is Drawing Attention Now STAAR Surgical (STAA) is back on investors’ radar after a volatile period, with the stock up over the past 3 months but down over the past month and past year. See our latest analysis for STAAR Surgical. Recent trading paints a mixed picture for STAAR Surgical, with the share price at $28.37 after a 90 day share price return of 58.94%, but a 5 year total shareholder return that declined 80.85%. This suggests near term momentum in contrast with...
Uppdatering av berättelse • Jun 16
STAA: China Rebound After Q1 Inflection Will Drive Future Re Rating
STAAR Surgical's analyst price target has been reset from $23.00 to about $39.24, with analysts pointing to stronger than expected Q1 results, signs of a China rebound, and updated long term assumptions on valuation multiples, even as management holds back on formal guidance. Analyst Commentary Recent Street research around STAAR Surgical has turned more constructive, with several bullish analysts lifting price targets and, in some cases, upgrading their ratings following the latest Q1 report.
Uppdatering av berättelse • Jun 02
STAA: China Recovery And Profitability Improvements Will Temper Prior Bearish Reassessment
The analyst price target for STAAR Surgical has shifted from $21.11 to $29.67 as analysts factor in Q1 results that were ahead of expectations, a stronger China contribution, and slightly higher modeled profitability, even as revenue growth assumptions and the projected future P/E are revised. Analyst Commentary Recent research shows a clear shift in sentiment around STAAR Surgical, with several firms lifting price targets following Q1 results that were ahead of expectations.Uppdatering av berättelse • May 15
STAA: Limited China Visibility And Missing Guidance Will Restrain Future Share Performance
Analysts have raised the fair value estimate for STAAR Surgical stock from $13.00 to $16.00, citing higher price targets supported by stronger Q1 results, improving confidence in a China rebound, and updated models that reflect better profitability assumptions and a lower future P/E multiple. Analyst Commentary Street research on STAAR Surgical has turned more constructive around the recent Q1 update, but the tone is not uniformly positive.Uppdatering av berättelse • Apr 20
STAA: China Uncertainty And Leadership Transition Will Drive Bearish Reassessment
STAAR Surgical's updated fair value estimate shifts from $26.56 to $21.11 as analysts factor in revised Street targets. These include recent cuts to around $18 to $22 that reflect questions on China exposure and mixed near term visibility, despite some more supportive views emerging.Uppdatering av berättelse • Apr 06
STAA: China Clarity And Post Alcon Reset Will Drive Future Re Rating
Analysts have trimmed price targets on STAAR Surgical to a range around $18 to $22, with a consensus reset of approximately $23.00, reflecting ongoing questions about China exposure, recent Q4 volatility, and limited near term visibility following the rejected Alcon deal. Analyst Commentary Recent Street commentary around STAAR Surgical centers on uncertainty, but there are pockets of optimism that readers should weigh alongside the more cautious views.Uppdatering av berättelse • Mar 23
STAA: Ongoing China Uncertainty And Governance Turmoil Will Pressure Shares
Analysts have reduced the consolidated price target for STAAR Surgical to $22 from $28, reflecting lower assumptions for revenue growth and profit margins, a much higher future P/E multiple, and ongoing uncertainty around China and the company’s broader path forward. Analyst Commentary Recent Street research on STAAR Surgical points to a cautious tone, with multiple bearish analysts cutting price targets and reiterating neutral or underweight stances.Uppdatering av berättelse • Mar 09
STAA: China Clarity And Post Alcon Reset Will Shape Future Upside Potential
Narrative Update on STAAR Surgical Our analyst price target for STAAR Surgical has been revised from $30.75 to $23.00 as analysts factor in recent target cuts, ongoing uncertainty around China and limited near term visibility highlighted in the latest research. Analyst Commentary Recent research on STAAR Surgical has leaned cautious, with multiple firms revising price targets lower and emphasizing uncertainty around the company’s outlook, particularly related to China and the failed Alcon transaction.Uppdatering av berättelse • Feb 23
STAA: Post Deal Rejection Concerns Will Keep Shares Under Pressure
Analysts have reduced their average price targets on STAAR Surgical by high single digit dollar amounts to around $13.00. This reflects more cautious views on profit margins and valuation multiples after the failed Alcon deal and a series of Neutral and Underweight ratings.Uppdatering av berättelse • Feb 08
STAA: Post Deal Collapse Uncertainty Will Pressure Shares Until Leadership Path Clears
Narrative Update on STAAR Surgical The analyst price target for STAAR Surgical has been reduced by US$8.75 following a neutral initiation, an Underweight resumption, and cautious commentary from several firms who highlight limited investor appetite until there is greater clarity on the company after the failed Alcon transaction. Analyst Commentary Recent Street research around STAAR Surgical has leaned cautious, with several firms highlighting valuation, execution, and growth risks following the failed Alcon transaction and the subsequent shareholder vote.Uppdatering av berättelse • Jan 25
STAA: Post Alcon Deal Collapse And CEO Exit Will Cap Near Term Upside
Analysts have trimmed their fair value estimate for STAAR Surgical from US$17.41 to US$13.00, reflecting lower assumed revenue growth and a reduced future P/E multiple, alongside cautious commentary around limited buyer interest and uncertainty following the failed Alcon deal. Analyst Commentary Recent Street research has tilted clearly cautious, with several bearish analysts highlighting valuation pressure, deal uncertainty, and limited near term visibility on the business.Uppdatering av berättelse • Jan 10
STAA: Failed Alcon Deal And Takeover Optionality Will Reshape Future Appeal
Analysts have lifted their fair value estimate for STAAR Surgical shares from US$28.00 to US$30.75, reflecting updated assumptions on growth, margins and future P/E multiples after recent debate over the failed Alcon deal and the limited near term appeal highlighted in recent research. Analyst Commentary Recent research has centered on the failed Alcon transaction, shareholder pushback on deal terms, and the limited near term appeal cited by several firms.Uppdatering av berättelse • Dec 26
STAA: Amended Alcon Deal And Activist Push Will Drive Bullish Upside
Analysts have nudged their fair value estimate for STAAR Surgical higher from approximately $25.88 to $26.56. This reflects modestly stronger growth and margin expectations while acknowledging that any amended Alcon deal is unlikely to include a materially higher bid.Uppdatering av berättelse • Dec 12
STAA: Merger Uncertainty Will Restrain Upside Despite Higher All-Cash Offer
Analysts have modestly raised their price target on STAAR Surgical from $16.00 to approximately $17.41 per share, citing slightly improved assumptions for long term revenue growth, profitability, and future valuation multiples, while they continue to monitor ongoing merger term discussions with Alcon. Analyst Commentary Bearish analysts highlight that the postponed shareholder meeting reinforces uncertainty around the timing and ultimate outcome of the proposed acquisition, which in turn clouds visibility on STAAR Surgical's standalone valuation.Uppdatering av berättelse • Nov 28
STAA: Amended Merger Terms And Shareholder Opposition Will Guide Share Price Direction
Analysts have maintained their price target for STAAR Surgical at $25.88, citing limited expected upside due to ongoing merger negotiations and continued uncertainty regarding the acquisition terms. Analyst Commentary Market commentary surrounding STAAR Surgical’s ongoing merger negotiations reflects mixed analyst sentiment, with both cautious and optimistic perspectives regarding the company’s prospects and valuation.Uppdatering av berättelse • Nov 12
STAA: Merger Discussions and Shareholder Opposition Will Shape Path Forward
Analysts have revised STAAR Surgical's price target downward to $16 from previous levels. They cite ongoing shareholder opposition to the proposed merger terms and uncertainty about a potential acquisition price.Uppdatering av berättelse • Oct 29
Board Opposition And Postponed Vote Will Shape Acquisition Outcome In 2025
Analysts have raised their average price target for STAAR Surgical from $20 to $28 per share. They cite the strategic rationale and valuation of the proposed acquisition by Alcon as key drivers for the upward revision.Uppdatering av berättelse • Oct 15
Introduction Of EVO+ Will Open Market Opportunities In 2025
Analysts have raised their price target for STAAR Surgical from $24.63 to $25.88. This reflects the impact of an increased acquisition offer and the perceived strategic value from Alcon's proposed purchase.Uppdatering av berättelse • Aug 20
Introduction Of EVO+ Will Open Market Opportunities In 2025
Analysts have raised their price targets for STAAR Surgical primarily to reflect the proposed $28/share acquisition by Alcon, which sets a new benchmark valuation and limits further upside, resulting in a new consensus fair value of $24.14. Analyst Commentary Bullish analysts raised their price targets to align with the proposed $28/share acquisition price by Alcon.Uppdatering av berättelse • Aug 06
Introduction Of EVO+ Will Open Market Opportunities In 2025
Driven by a significant improvement in net profit margin despite a higher discount rate, STAAR Surgical's consensus price target has increased from $19.20 to $22.11. What's in the News Alcon Inc.Analysartikel • Jul 04
Getting In Cheap On STAAR Surgical Company (NASDAQ:STAA) Might Be Difficult
There wouldn't be many who think STAAR Surgical Company's ( NASDAQ:STAA ) price-to-sales (or "P/S") ratio of 3.2x is...Analysartikel • Apr 05
Is STAAR Surgical Company (NASDAQ:STAA) Trading At A 37% Discount?
Key Insights The projected fair value for STAAR Surgical is US$25.07 based on 2 Stage Free Cash Flow to Equity Current...Analysartikel • Feb 14
Why Investors Shouldn't Be Surprised By STAAR Surgical Company's (NASDAQ:STAA) 26% Share Price Plunge
Unfortunately for some shareholders, the STAAR Surgical Company ( NASDAQ:STAA ) share price has dived 26% in the last...Seeking Alpha • Feb 12
STAAR Surgical Q4: Ongoing Challenges In China Masks Healthy Growth Elsewhere
Summary STAAR Surgical's Q4 results were severely impacted by lower demand and high inventory levels in China. Global growth ex-China was 17% in Q4 and is expected to remain strong at 12% for FY25, with US growth of close to 15%. Cash burn is expected to be significant, but the company is financially healthy, having $232 million in cash and no debt on its balance sheet. Following the post-earnings drop, shares are cheaply valued given the long growth runway ahead, which leads me to maintain my Buy rating on STAA stock. Read the full article on Seeking AlphaSeeking Alpha • Jan 31
STAAR Surgical: Growth Story Remains Intact Despite Some Challenges
Summary Shares have been under pressure lately due to weak demand from China, which is by far the company’s largest market. The market opportunity in the US remains large, and management is investing heavily to tap into it. I have modest expectations for overall growth in FY25 of 9%, with markets excluding China growing significantly faster. The FCF margin in FY25 is expected to be around 8.3% given the ongoing growth investments, while I expect that it can reach close to 20% in the long term. I am assigning a Buy rating on the stock with a target priceof $35, implying an upside of over 45%. Read the full article on Seeking AlphaAktieägarnas avkastning
| STAA | US Medical Equipment | US Marknad | |
|---|---|---|---|
| 7D | -8.1% | 1.6% | -0.2% |
| 1Y | -23.6% | -16.3% | 11.9% |
Avkastning vs industri: STAA presterade sämre än US Medical Equipment branschen som gav -16.3 % under det senaste året.
Avkastning vs Marknaden: STAA presterade sämre än US marknaden som gav 11.9 % under det senaste året.
Prisvolatilitet
| STAA volatility | |
|---|---|
| STAA Average Weekly Movement | 7.5% |
| Medical Equipment Industry Average Movement | 8.2% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in US Market | 15.0% |
| 10% least volatile stocks in US Market | 2.9% |
Stabil aktiekurs: STAA har inte haft någon betydande prisvolatilitet under de senaste 3 månaderna jämfört med marknaden för US.
Volatilitet över tid: STAA s veckovolatilitet ( 7% ) har varit stabil under det senaste året.
Om företaget
| Grundad | Anställda | VD OCH KONCERNCHEF | Webbplats |
|---|---|---|---|
| 1982 | 921 | Warren Foust | www.staar.com |
STAAR Surgical Company, tillsammans med sina dotterbolag, designar, utvecklar, tillverkar och säljer fakiska implanterbara linser för ögat och tillbehör för att föra in linserna i ögat. Företaget erbjuder en produktfamilj av implanterbara kollamerlinser (ICL) bestående av EVO ICL, EVO+ ICL, EVO Visian ICL och EVO Viva ICL för användning vid brytningsoperationer för behandling av synfel som närsynthet, översynthet, astigmatism och ålderssynthet. Företaget vänder sig till vårdgivare, inklusive ögonkirurger, syn- och operationscentra, sjukhus, statliga inrättningar och distributörer samt ögonläkare.
STAAR Surgical Company Sammanfattning av grunderna
| STAA grundläggande statistik | |
|---|---|
| Börsvärde | US$1.07b |
| Vinst(TTM) | US$3.84m |
| Intäkter(TTM) | US$339.59m |
271.9x
P/E-förhållande3.1x
P/S-förhållandeÄr STAA övervärderat?
Se Verkligt värde och värderingsanalysResultat & intäkter
| STAA resultaträkning (TTM) | |
|---|---|
| Intäkter | US$339.59m |
| Kostnad för intäkter | US$79.39m |
| Bruttovinst | US$260.20m |
| Övriga kostnader | US$256.36m |
| Intäkter | US$3.84m |
Senast redovisade vinst
Jul 03, 2026
Nästa vinstdatum
n/a
| Vinst per aktie (EPS) | 0.077 |
| Bruttomarginal | 76.62% |
| Nettovinstmarginal | 1.13% |
| Skuld/egenkapitalförhållande | 0% |
Hur har STAA utvecklats på lång sikt?
Se historisk utveckling och jämförelseFöretagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/09/18 11:48 |
| Aktiekurs vid dagens slut | 2026/09/18 00:00 |
| Intäkter | 2026/07/03 |
| Årlig intjäning | 2026/01/02 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som används för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och handledningar på Youtube.
Lär dig mer om det som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
STAAR Surgical Company bevakas av 20 analytiker. 12 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Michael Gorman | BTIG |
| William Plovanic | Canaccord Genuity |
| John Young | Canaccord Genuity |